Aurobindo Pharma share news, announcements and annual reports

NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap

Aurobindo Pharma Limited · Face value ₹1 · Listed Apr 1995 on BSE, Jul 2000 on NSE

₹1,681.40₹21.50 (1.30%)BSE ₹1,677.80

Share price at the NSE close on 30 Oct 2026. Previous close ₹1,659.90.

30 Oct: open ₹1,652.00, high ₹1,687.00, low ₹1,647.20

52-week range of traded prices to 30 Oct 2026

₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026

Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar

Market cap: ₹96,744 Cr138th largest listed
P/E: 26.06
P/B: 2.55
Dividend yield: Nonein the last 12 months
ROE: 10.5%
ROCE: 11.5%
Debt to equity: 0.20
Volume, NSE: 9,52,65057.5% delivered

Aurobindo Pharma share news and announcements

1,689 announcements, routine notices left out, newest first. Page 24 of 34.

Jul 2014
- 1 Jul · Management
  Mr. Sudhir B Singhi, Chief Financial Officer (CFO) of the Company has relinquished his duties with effect from 1st July 2014 due to his personal reasons. Mr. Santhanam Subramanian has been appointed as CFO of the Company with effect from 1st July 2014. Mr. Subramanian, a Chartered Accountant, Cost Accountant and Company Secretary has around 30 years of experience and in the past associated with reputed companies in senior positions. He has been with Aurobindo since November, 2013. The Board placed on record its appreciation for Mr. Singhi's significant contribution during his long association with the Company in aligning the overall financial strategy to Company s vision for fuelling its expansion and dynamic business needs. Mr. Singhi will be relocated to Mumbai as Corporate Financial Advisor and will assist the Company in its strategic finance function
Jun 2014
May 2014
- 31 May · Meeting
  Company has fixed Book Closure from August 19, 2014 to August 27, 2014 (both days inclusive) for the purpose of Annual General Meeting of the company to be held on August 27, 2014
- 31 May · Dividend
  Interim dividend will be paid on or before June 25, 2014.
- 31 May · Corporate action
  Company has fixed Record Date as June 12, 2014 for the purpose of payment of Second Interim Dividend for the year 2013-14.
- 31 May · Business
  Press release dated May 30, 2014 "FY 2013-14 Audited Financials".
- 31 May · Dividend
  Board of Directors of the Company at its meeting held on 30.05.2014 has inter-alia considered and approved second interim dividend of 175% (Rs.1.75 per equity share of Re.1/- each) on the equity share capital of the Company for the year 2013-14. The Company in the month of November 2013 has paid an interim dividend of 125% (Re.1.25 per equity share of Re.1/- each) on the equity share capital of the Company for the year 2013-14. Thus the total dividend, including the second interim dividend for the year ended 31st March, 2014 will aggregate to 300% (Rs.3.00 per equity share of Re.1/- each) on the equity share capital of the Company for the year 2013-14. The Board of Directors do not recommend any further dividend for the year 2013-14.
- 30 May · Results
  Standalone & consolidated financial results for the period ended 31-Mar-2014.
- 19 May · Board meeting
  Inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2014. Further at the said Board meeting the Board will also consider recommendation of Final Dividend, if any, for the year 2013-14.
- 12 May · Business
  Hon ble High Court of Judicature of Andhra Pradesh at Hyderabad has sanctioned the Scheme of Arrangement between Aurobindo Pharma Limited and Curepro Parenterals Limited and their respective shareholders and creditors ( Scheme ) under Sections 391 to 394 of the Companies Act, 1956. The Scheme provides for transfer of Injectables Unit IV of Aurobindo to Curepro, its wholly-owned subsidiary, with effect from the Appointed Date April 1, 2014.
- 12 May · Updates
  Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has sanctioned the Scheme of Arrangement between Aurobindo Pharma Limited and Curepro Parenterals Limited and their respective shareholders and creditors ("Scheme") under Sections 391 to 394 of the Companies Act, 1956. The Scheme provides for transfer of injectables Unit IV of Aurobindo to Curepro, its wholly-owned subsidiary, with effect from the Appointed Date April 01, 2014. The Company shall take necessary steps to make the Scheme effective and will intimate the exchanges accordingly.
Apr 2014
- 4 Apr · Disclosure
  Vide letter dated April 04, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011,along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.
- 1 Apr · Business
  Press Release dated April 01, 2014 titled "Aurobindo completes the acquisition of select Western European Businesses of Actavis".
Mar 2014
Feb 2014
- 6 Feb · Business
  Press Release dated February 06, 2014 titled "Aurobindo Pharma 3Q 2013-14 Unaudited Results".
- 6 Feb · Results
  Standalone Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 189291 lacs for the quarter ending on 31-DEC-2013 against Rs. 158162 lacs and Rs. 141263 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively. Net Profit / (Loss) of Rs. 41816 lacs for the quarter ending on 31-DEC-2013 against Rs. 17970 lacs and Rs. 14428 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively.
- 6 Feb · Results
  Consolidated Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 213552 lacs for the quarter ending on 31-DEC-2013 against Rs. 189748 lacs and Rs. 155195 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively. Net Profit / (Loss) of Rs. 41749 lacs for the quarter ending on 31-DEC-2013 against Rs. 23495 lacs and Rs. 9181 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively.
- 6 Feb · Results
  Standalone & consolidated financial results for the period ended 31-Dec-2013.
Jan 2014
- 28 Jan · Court Convened Meeting Updates
  At the Court convened meeting held on January 27, 2014, the shareholders approved the Scheme of Arrangement between Aurobindo Pharma Limited and Curepro Parenterals Limited,
- 23 Jan · Business
  Press Release dated January 23, 2014 titled "Aurobindo Pharma receives USFDA approval for Repaglinide Tablets".
- 22 Jan · Board meeting
  To consider inter alia, the Un-Audited Financial Results of the Company for the quarter ended December 31, 2013.
- 20 Jan · Business
  Press release dated January 18, 2014, titled " Aurobindo's European Subsidiary signs Binding Offer to acquire commercial operations in seven Western European Countries from Actavis".
- 10 Jan · Disclosure
  Vide letter dated January 10, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.
- 9 Jan · Disclosure
  Company on January 09, 2014 has made allotment of 1,27,500 Equity Shares of Re.1/- each at a premium of Rs. 90.60 per share under ESOP-2006 Scheme of the Company. Consequent to the allotment, the paid up share capital of the Company has increased from 29,12,11,290 Equity Shares of Re.1/- each to 29,13,38,790 Equity Shares of Re.1/- each.
- 9 Jan · Legal
  In response to news appearing in certain section of the press about a boiler blast in one of Aurobindo Pharma's units yesterday, the Company clarifies that there has been no such incidence and cautions all shareholders and investors not to take cognizance of these unverified reports.
- 2 Jan · Disclosure
  Vide letter dated January 02, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.
- 2 Jan · Court Convened Meeting Updates
  Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has directed by an order dated December 18, 2013 that meeting of the Equity Shareholders of the Company be convened to be held on January 27, 2014 for the purpose of considering the Scheme of Arrangement between Aurobindo Pharma Limited and Curepro Parenterals Limited and their respective Shareholders.
Dec 2013
- 13 Dec · Business
  Press release dated December 13, 2013, titled, "Aurobindo Pharma receives USFDA approval for Duloxetine Hydrochloride Delayed Release Capsules'.
Nov 2013
- 21 Nov · Disclosure
  Vide letter dated November 21, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.
- 20 Nov · Disclosure
  Vide letter dated November 20, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.
- 14 Nov · Updates
  At around 6 PM on November 13, 2013, there was a fire incident in intermediate manufacturing block at Unit-11 (manufacturing Active Pharmaceutical Ingredients), located at Pydibhimavaram, Srikakulam near Vizag, A.P.This is an isolated block from the main production area. There was no impact to the manufacturing operations, supplies and no major damage of assets. There has not been any a human casualty or injuries.
- 8 Nov · Results
  Standalone & consolidated financial results for the period ended 30-sep-2013.
- 8 Nov · Dividend
  Interim Dividend will be paid on or after November 27, 2013.
- 8 Nov · Corporate action
  Company has fixed Record Date as November 20, 2013 for the purpose of Interim Dividend 2013-14.
- 8 Nov · Business
  Press release dated November 07, 2013, titled "Aurobindo Pharma Q2/H1 2013-14 Unaudited Results".
- 8 Nov · Dividend
  Board of Directors of the Company at its meeting held on November 07, 2013 has approved payment of an Interim Dividend @ 125% i.e. Rs.1.25 (Rupee one and paise twenty five only) per Equity Share of Re.1/- (Rupee one only) each to the members of the Company for the Financial Year 2013-14.
Oct 2013
- 22 Oct · Board meeting
  To consider inter alia, the Un-Audited Financial Results of the Company for the quarter and half year ended September 30,2013.
Sep 2013
- 12 Sep · Board meeting
  Outcome of the Board Meeting held on September 12, 2013.
Aug 2013

Aurobindo Pharma share news and announcements

Jul 2014

Jun 2014

May 2014

Apr 2014

Mar 2014

Feb 2014

Jan 2014

Dec 2013

Nov 2013

Oct 2013

Sep 2013

Aug 2013